Cabazitaxel linked to lower treatment costs in third-line mCRPC

Video

Alicia Morgans, MD, MPH, discusses a health economics analysis presented at the 2021 ESMO Congress that assessed the clinical and cost impact of cabazitaxel (Jevtana) versus a second-androgen receptor targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone acetate [Zytiga] or enzalutamide [Xtandi]).1 Morgans and coinvestigators based their analysis on data from 100 patients treated in this setting, with inputs from the CARD trial, medical literature, and estimates (by 3 GU oncologists) of typical clinical care patterns.

As point of reference, the results of the CARD trial previously showed that third-line cabazitaxel (post docetaxel and after 1 year of abiraterone or enzalutamide) significantly improved progression-free survival (PFS; HR, 0.54; P <.001) and overall survival (OS; HR, 0.64; P =.008).2 The use of cabazitaxel also showed a clinically meaningful improvement in pain response and time to skeletal-related events versus abiraterone or enzalutamide.2

In their ESMO abstract conclusion, Morgans et al wrote that their health economic analysis showed that, “The use of cabazitaxel as a third-line treatment after docetaxel and ARTA in mCRPC pts is predicted to result in clinical benefits (longer rPFS, OS) and fewer hospitalization and ICU days. Compared to a second ARTA, cabazitaxel was estimated to be associated with a 21% reduction in both symptomatic skeletal event and end-of-life care costs and a 10% increase in adverse event costs, for an overall decrease of 17% in costs.”1

Morgans is a genitourinary medical oncologist and the medical director of the Survivorship Program at Dana-Farber Cancer Institute.

References

1. Morgans AK, Hutson TE, Guan AK, et al. Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide). Presented at: 2021 European Society of Medical Oncology Congress; September 16-21, 2021; Virtual. Abstract 587P.

2. de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381(26):2506-2518. doi: 10.1056/NEJMoa1911206

Related Videos
Dr. Jasmeet Kaur in an interview with Urology Times
Dr. Martin Voss in an interview with Urology Times
Dr. Jacqueline Brown in an interview with Urology Times
blurred clinic hallway
Dr. Dalia Kaakour in an interview with red Urology Times backdrop
Dr. Maria Teresa Bourlon in an interview with Urology Times
Dr. David Braun in an interview with Urology Times
Dr. Neeraj Agarwal in an interview with Urology Times
Dr. Saby George in an interview with Urology Times
Dr. Laura Bukavina in an interview with Urology Times
Related Content
© 2024 MJH Life Sciences

All rights reserved.